127 related articles for article (PubMed ID: 29958636)
61. Delusional infestation: a case for preserving pimozide as an option.
Jeon C; Koo J
J Dermatolog Treat; 2022 Aug; 33(5):2705. PubMed ID: 35373694
[No Abstract] [Full Text] [Related]
62. Why is pimozide uniquely useful for the treatment of delusional patients in dermatology?
Brownstone N; Koo J
J Dermatolog Treat; 2022 May; 33(3):1779. PubMed ID: 32940111
[No Abstract] [Full Text] [Related]
63. Drug-induced yawning successfully treated with pimozide.
Rollison RD; Wiggins WS; Gilligan BS
Arch Neurol; 1979 Apr; 36(4):253. PubMed ID: 371596
[No Abstract] [Full Text] [Related]
64. Glioblastoma cytotoxicity conferred through dual disruption of endolysosomal homeostasis by Vacquinol-1.
Kwak D; Hammarström LGJ; Haraldsson M; Ernfors P
Neurooncol Adv; 2021; 3(1):vdab152. PubMed ID: 34765974
[TBL] [Abstract][Full Text] [Related]
65. Glioblastoma radiosensitization by pimozide.
Rath BH; Camphausen K; Tofilon PJ
Transl Cancer Res; 2016 Nov; 5(Suppl 6):S1029-S1032. PubMed ID: 32999862
[No Abstract] [Full Text] [Related]
66. Open study to determine appropriate maintenance dosage of pimozide in patients with chronic schizophrenia.
Barnes TR; Roy DH; Gaind R
Proc R Soc Med; 1977; 70(Suppl 10):44-7. PubMed ID: 20919318
[No Abstract] [Full Text] [Related]
67. Sensitizing glioblastoma to radiotherapy.
Crunkhorn S
Nat Rev Drug Discov; 2021 Aug; 20(8):588. PubMed ID: 34234306
[No Abstract] [Full Text] [Related]
68. Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".
Simonelli M; Persico P; Perrino M; Zucali PA; Navarria P; Pessina F; Scorsetti M; Bello L; Santoro A
Cancer Treat Rev; 2018 Sep; 69():121-131. PubMed ID: 29966936
[TBL] [Abstract][Full Text] [Related]
69. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.
Shaw V; Srivastava S; Srivastava SK
Semin Cancer Biol; 2021 Jan; 68():75-83. PubMed ID: 31618686
[TBL] [Abstract][Full Text] [Related]
70. Inhibition of cancer stem cells promoted by Pimozide.
Gonçalves JM; Silva CAB; Rivero ERC; Cordeiro MMR
Clin Exp Pharmacol Physiol; 2019 Feb; 46(2):116-125. PubMed ID: 30383889
[TBL] [Abstract][Full Text] [Related]
71. Pimozide Suppresses the Growth of Brain Tumors by Targeting STAT3-Mediated Autophagy.
Ranjan A; Kaushik I; Srivastava SK
Cells; 2020 Sep; 9(9):. PubMed ID: 32971907
[TBL] [Abstract][Full Text] [Related]
72. A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.
Aslostovar L; Boyd AL; Almakadi M; Collins TJ; Leong DP; Tirona RG; Kim RB; Julian JA; Xenocostas A; Leber B; Levine MN; Foley R; Bhatia M
Blood Adv; 2018 Aug; 2(15):1935-1945. PubMed ID: 30093531
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5.
Woo SM; Kim S; Seo SU; Kim S; Park JW; Kim G; Choi YR; Hur K; Kwon TK
Cell Death Dis; 2022 Sep; 13(9):821. PubMed ID: 36153316
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.
Li XY; Wu JC; Liu P; Li ZJ; Wang Y; Chen BY; Hu CL; Fei MY; Yu PC; Jiang YL; Xu CH; Chang BH; Chen XC; Zong LJ; Zhang JY; Fang Y; Sun XJ; Xue K; Wang L; Chen SB; Jiang SY; Gui AL; Yang L; Gu JJ; Yu BH; Zhang QL; Wang L
Leukemia; 2023 Jan; 37(1):164-177. PubMed ID: 36352191
[TBL] [Abstract][Full Text] [Related]
75. USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
Lim KS; Li H; Roberts EA; Gaudiano EF; Clairmont C; Sambel LA; Ponnienselvan K; Liu JC; Yang C; Kozono D; Parmar K; Yusufzai T; Zheng N; D'Andrea AD
Mol Cell; 2018 Dec; 72(6):925-941.e4. PubMed ID: 30576655
[TBL] [Abstract][Full Text] [Related]
76. Ubiquitin-specific peptidase 1: assessing its role in cancer therapy.
Huang P; Wang Y; Zhang P; Li Q
Clin Exp Med; 2023 Nov; 23(7):2953-2966. PubMed ID: 37093451
[TBL] [Abstract][Full Text] [Related]
77. Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders.
Kitamura H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834633
[TBL] [Abstract][Full Text] [Related]
78. Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer.
Simoneau A; Engel JL; Bandi M; Lazarides K; Liu S; Meier SR; Choi AH; Zhang H; Shen B; Martires L; Gotur D; Pham TV; Li F; Gu L; Gong S; Zhang M; Wilker E; Pan X; Whittington DA; Throner S; Maxwell JP; Chen Y; Yu Y; Huang A; Andersen JN; Feng T
Mol Cancer Ther; 2023 Feb; 22(2):215-226. PubMed ID: 36228090
[TBL] [Abstract][Full Text] [Related]
79. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.
Tyagi A; Kaushal K; Chandrasekaran AP; Sarodaya N; Das S; Park CH; Hong SH; Kim KS; Ramakrishna S
Theranostics; 2022; 12(13):5949-5970. PubMed ID: 35966591
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
